Abstract:RationaleProteomics and metabolomics are widely used in the study of diabetes, but rarely in prediabetes research. This study aimed to explore the mechanisms of early-onset type 2 diabetes mellitus (T2DM) by analyzing proteomic changes at different stages of glucose metabolism. MethodsA total of 40 individuals undergoing routine physical health examinations between December 2016 and April 2017 were enrolled. Subjects were divided into four groups based on fasting blood glucose (FPG) levels: FPG < 5.6 mmol/L (group A); FPG >= 5.6 mmol/L and <6.1 mmol/L (group B); FPG >= 6.1 mmol/L and <7.0 mmol/L (group C); and FPG >= 7.0 mmol/L (group D). Each group had 10 cases. Sera from these 40 subjects were analyzed by label-free quantitative liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). LC/MS/MS with selected reaction monitoring mode was also performed for qualitative and quantitative metabolomics analysis. Differentially expressed proteins were identified. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to analyze the differentially expressed metabolites. ResultsA total of 202 differentially expressed proteins were screened and were identified as mainly secreted proteins. Comparing group A with group B, 32 proteins were up-regulated and 18 proteins were down-regulated. Comparing group A with group C, 24 proteins were up-regulated and 24 proteins were down-regulated. Comparing group A with group D, 19 proteins were up-regulated and 17 proteins were down-regulated. The fold change for up-regulated proteins was >1.2, p < 0.05, while the fold change for down-regulated proteins was <-1.2, p < 0.05. PLS-DA and OPLS-DA revealed 113 differentially expressed metabolites. Correlation analysis of differentially expressed metabolites of group A versus group B revealed that among the down-regulated differential proteins, transforming growth factor beta-induced protein ig-h3 correlated negatively with metabolite L-saccharin, while among the up-regulated differential proteins, apolipoprotein C-IV correlated negatively with metabolite 3-methyloxindole. Among all differentially expressed proteins, 19 proteins were associated with early initiation of chronic inflammation, including CD14 and CSF-1R, which were newly identified in the early onset of T2DM. ConclusionsMany proteins are differentially expressed between prediabetes and after T2DM diagnosis, although the specific mechanism remains unclear. The expression level of CD14 was significantly up-regulated and that of CSF-1R was significantly down-regulated when FPG was >= 5.6 mmol/L, suggesting that CD14 and CSF-1R may be important markers for early-onset T2DM and may serve as new targets for T2DM treatment.

A New Strategy For Early Diagnosis Of Type 2 Diabetes By Standard-Free, Label-Free Lc-Ms/Ms Quantification Of Glycated Peptides

The Tryptic Peptides of Hemoglobin for Diagnosis of Type 2 Diabetes Mellitus Using Label-Free and Standard-Free LC-ESI-DMRM

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Discovery and validation of glucose-sensitive peptide biomarkers from human serum albumin to diagnose type 2 diabetes mellitus

Application of a Pseudotargeted MS Method for the Quantification of Glycated Hemoglobin for the Improved Diagnosis of Diabetes Mellitus

Screening for Potential Serum-Based Proteomic Biomarkers for Human Type 2 Diabetes Mellitus Using Maldi-Tof Ms

Serological Phenotyping Analysis Uncovers a Unique Metabolomic Pattern Associated With Early Onset of Type 2 Diabetes Mellitus

Glycated lysine-141 in haptoglobin improves the diagnostic accuracy for type 2 diabetes mellitus in combination with glycated hemoglobin HbA1c and fasting plasma glucose

A-031 Global Discovery of Serological Metabolome Uncovers Unique Molecular Signature for Early Onset of Type 2 Diabetes Mellitus: A Retrospective Study in Chinese Population

A Metabolic Profiling Strategy for Biomarker Screening by Gc-Ms Combined with Multivariate Resolution Method and Monte Carlo Pls-Da

Metabolomics and Lipidomics Studies in Pediatric Type 1 Diabetes: Biomarker Discovery for the Early Diagnosis and Prognosis

Phospholipidomic Identification of Potential Plasma Biomarkers Associated with Type 2 Diabetes Mellitus and Diabetic Nephropathy.

Integrated Strategy for Discovery and Validation of Glycated Candidate Biomarkers for Hemodialysis Patients with Cardiovascular Complications.

Practical Analytical Approach for the Identification of Biomarker Candidates in Prediabetic State Based Upon Metabonomic Study by Ultraperformance Liquid Chromatography Coupled to Electrospray Ionization Time-of-flight Mass Spectrometry.

Determination of plasma methylglyoxal and glyoxal concentrations in patients with diabetes mellitus by high-performance liquid chromatographic/tandem mass spectrometry

Identification of free fatty acids profiling of type 2 diabetes mellitus and exploring possible biomarkers by GC–MS coupled with chemometrics

Plasma phospholipid metabolic profiling and biomarkers of type 2 diabetes mellitus based on high-performance liquid chromatography/electrospray mass spectrometry and multivariate statistical analysis.

Lipidomics based on UHPLC/Q-TOF-MS to characterize lipid metabolic profiling in patients with newly diagnosed type 2 diabetes mellitus with dyslipidemia

SERS-based Detection of Early Type 1 Diabetes Mellitus Biomarkers: Glutamate Decarboxylase Antibody and Insulin Autoantibody

Hydrophilic interaction liquid chromatography coupled with tandem mass spectrometry method for the simultaneous determination of l-valine, l-leucine, l-isoleucine, l-phenylalanine, and l-tyrosine in human serum.

Establishment and Optimization of Peptide Biomarker Screening Model in Diabetes in Vitro by HPLC/ESI-TOF Mass Spectrometry